|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Proteon Therapeutics, Inc.
| | | Phone: | (781) 890-0102 | Fax: | (781) 487-6729 | Year Established: | 2001 | Ticker: | PRTO | Exchange: | NASDAQ | Main Contact: | Daniel P. Gottlieb, VP, Corporate Development | | Other Contacts: | John Najim, VP, Manufacturing and Process Development Pamela Gustafson, VP, Clinical Research Scott Toner, Senior VP, Marketing Steven K. Burke, M.D., Senior VP & CMO Marco D. Wong, M.D., Ph.D., Medical Director Timothy P. Noyes, President & CEO
| | Company Description | Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon is currently enrolling patients in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with CKD undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial of vonapanitase in patients with PAD. | |
|
|
|
|
|